Boston Scientific names Fitzgerald COO: What it means for Boston Scientific stock
Published on 10/10/2026 at 10:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Joseph M. Fitzgerald will become Boston Scientific’s COO on January 1, 2027.
- The company will establish three reportable segments on the same date.
- BSX was last quoted at USD 42.73 on October 9, 2026, versus a USD 42.04 prior close.
On October 7, 2026, Boston Scientific Corporation announced that Joseph M. Fitzgerald will become executive vice president and chief operating officer effective January 1, 2027. Fitzgerald will oversee the company’s global operations, business units and regions.
Boston Scientific was last quoted at USD 42.73 on October 9, 2026, compared with a prior close of USD 42.04, according to finance market data. The quote is separate from the company’s October 7 announcement.
Market context: Market report S&P 500.
The week in figures
The latest available U.S. quote was USD 42.73 on October 9, 2026, against a prior close of USD 42.04. No weekly high or low is included in the available market record.
Chronology of the week
On October 7, 2026, Boston Scientific announced Fitzgerald’s appointment and said three reportable segments will be established on January 1, 2027: Interventional Therapies, Rhythm Solutions and MedSurg.
Dates of the coming week
The next Xetra session is scheduled for October 12, 2026. Boston Scientific’s announced operating changes take effect on January 1, 2027.
Company development
The company said Lance Bates will lead Interventional Therapies, Nick Spadea-Anello will lead Rhythm Solutions, and Stephen Morse will lead MedSurg and Asia Pacific. Each will report to Fitzgerald, according to Boston Scientific’s release.
